Literature DB >> 11443541

Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel.

H Toledano-Alhadef1, L Basel-Vanagaite, N Magal, B Davidov, S Ehrlich, V Drasinover, E Taub, G J Halpern, N Ginott, M Shohat.   

Abstract

Fragile-X syndrome is caused by an unstable CGG trinucleotide repeat in the FMR1 gene at Xq27. Intermediate alleles (51-200 repeats) can undergo expansion to the full mutation on transmission from mother to offspring. To evaluate the effectiveness of a fragile-X carrier-screening program, we tested 14,334 Israeli women of child-bearing age for fragile-X carrier status between 1992 and 2000. These women were either preconceptional or pregnant and had no family history of mental retardation. All those found to be carriers of premutation or full-mutation alleles were offered genetic counseling and also prenatal diagnosis, if applicable. We identified 207 carriers of an allele with >50 repeats, representing a prevalence of 1:69. There were 127 carriers with >54 repeats, representing a prevalence of 1:113. Three asymptomatic women carried the fully mutated allele. Among the premutation and full-mutation carriers, 177 prenatal diagnoses were performed. Expansion occurred in 30 fetuses, 5 of which had an expansion to the full mutation. On the basis of these results, the expected number of avoided patients born to women identified as carriers, the cost of the test in this study (U.S. $100), and the cost of lifetime care for a mentally retarded person (>$350,000), screening was calculated to be cost-effective. Because of the high prevalence of fragile-X premutation or full-mutation alleles, even in the general population, and because of the cost-effectiveness of the program, we recommend that screening to identify female carriers should be carried out on a wide scale.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443541      PMCID: PMC1235307          DOI: 10.1086/321974

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  39 in total

1.  Predisposition to the fragile X syndrome in Jews of Tunisian descent is due to the absence of AGG interruptions on a rare Mediterranean haplotype.

Authors:  T C Falik-Zaccai; E Shachak; M Yalon; Z Lis; Z Borochowitz; J N Macpherson; D L Nelson; E E Eichler
Journal:  Am J Hum Genet       Date:  1997-01       Impact factor: 11.025

2.  Familial transmission of the FMR1 CGG repeat.

Authors:  S L Nolin; F A Lewis; L L Ye; G E Houck; A E Glicksman; P Limprasert; S Y Li; N Zhong; A E Ashley; E Feingold; S L Sherman; W T Brown
Journal:  Am J Hum Genet       Date:  1996-12       Impact factor: 11.025

3.  [First trimester ultrasound screening for nuchal translucency as marker of Down's syndrome].

Authors:  A Herman; R Maymon; E Dreazen; I Bukovsky; Z Weinraub
Journal:  Harefuah       Date:  1997-01-15

4.  Ethnic distribution of the fragile X syndrome in Israel: evidence of founder chromosomes(?).

Authors:  H Dar; T Chemke; T Schaap; R Chaki; H Bait-Or; H Cohen; Z Borochowitz; Z Falik-Borenstein; Z Gelman-Kohan; J Chemke
Journal:  Isr J Med Sci       Date:  1995-05

5.  Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population.

Authors:  G Ginsberg; H Blau; E Kerem; C Springer; B S Kerem; E Akstein; A Greenberg; A Kolumbos; D Abeliovich; E Gazit
Journal:  Health Econ       Date:  1994 Jan-Feb       Impact factor: 3.046

6.  Population screening for fragile-X syndrome.

Authors:  P N Howard-Peebles; A Maddalena; S H Black; J D Schulman
Journal:  Lancet       Date:  1993-03-20       Impact factor: 79.321

7.  High throughput and economical mutation detection and RFLP analysis using a minimethod for DNA preparation from whole blood and acrylamide gel electrophoresis.

Authors:  F Rousseau; R Réhel; P Rouillard; P DeGranpré; E W Khandjian
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

8.  Fragile X screening program in New York State.

Authors:  S L Nolin; D A Snider; E C Jenkins; W T Brown; M Krawczun; D Stetka; G Houck; C S Dobkin; G Strong; G Smith-Dobransky
Journal:  Am J Med Genet       Date:  1991 Feb-Mar

9.  No founder effect detected in Jewish Ashkenazi patients with fragile-X syndrome.

Authors:  R Pesso; G Barkai; Y Ravia; E Gak; M Frydman; B Goldman; E Friedman
Journal:  Hum Genet       Date:  1997-12       Impact factor: 4.132

Review 10.  Advances in molecular analysis of fragile X syndrome.

Authors:  S T Warren; D L Nelson
Journal:  JAMA       Date:  1994-02-16       Impact factor: 56.272

View more
  65 in total

1.  Carrier screening in preconception consultation in primary care.

Authors:  Sylvia A Metcalfe
Journal:  J Community Genet       Date:  2011-12-20

2.  Identification of expanded alleles of the FMR1 gene among high-risk population in Indonesia by using blood spot screening.

Authors:  Tri Indah Winarni; Agustini Utari; Farmaditya E P Mundhofir; Tzuhan Tong; Blythe Durbin-Johnson; Sultana M H Faradz; Flora Tassone
Journal:  Genet Test Mol Biomarkers       Date:  2011-10-11

Review 3.  The impact of FMR1 gene mutations on human reproduction and development: a systematic review.

Authors:  Vincenzo Noto; Conor Harrity; David Walsh; Kevin Marron
Journal:  J Assist Reprod Genet       Date:  2016-07-18       Impact factor: 3.412

4.  Size bias of fragile X premutation alleles in late-onset movement disorders.

Authors:  Sebastien Jacquemont; Maureen A Leehey; Randi J Hagerman; Laurel A Beckett; Paul J Hagerman
Journal:  J Med Genet       Date:  2006-05-24       Impact factor: 6.318

Review 5.  A review of fragile X premutation disorders: expanding the psychiatric perspective.

Authors:  James A Bourgeois; Sarah M Coffey; Susan M Rivera; David Hessl; Louise W Gane; Flora Tassone; Claudia Greco; Brenda Finucane; Lawrence Nelson; Elizabeth Berry-Kravis; Jim Grigsby; Paul J Hagerman; Randi J Hagerman
Journal:  J Clin Psychiatry       Date:  2009-05-05       Impact factor: 4.384

6.  Prevalence of CGG expansions of the FMR1 gene in a US population-based sample.

Authors:  Marsha Mailick Seltzer; Mei Wang Baker; Jinkuk Hong; Matthew Maenner; Jan Greenberg; Daniel Mandel
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-22       Impact factor: 3.568

7.  The fragile X prevalence paradox.

Authors:  Paul J Hagerman
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

8.  Screening for intermediate CGG alleles of FMR1 gene in male Iranian patients with Parkinsonism.

Authors:  Atefeh Entezari; Mahmoud Shekari Khaniani; Tayyeb Bahrami; Sima Mansoori Derakhshan; Hossein Darvish
Journal:  Neurol Sci       Date:  2016-10-01       Impact factor: 3.307

Review 9.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009

10.  Polymerase chain reaction, nuclease digestion, and mass spectrometry based assay for the trinucleotide repeat status of the fragile X mental retardation 1 gene.

Authors:  Eric D Dodds; Flora Tassone; Paul J Hagerman; Carlito B Lebrilla
Journal:  Anal Chem       Date:  2009-07-01       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.